肝脏 ›› 2025, Vol. 30 ›› Issue (6): 773-776.

• 肝癌 • 上一篇    下一篇

GLUT-1、CDK4与原发性肝癌患者临床病理特征和预后关系分析

冯仕川, 沈勇   

  1. 723000 陕西汉中 汉中市中心医院全科医学科(冯仕川),介入与血管外科(沈勇)
  • 收稿日期:2024-08-09 出版日期:2025-06-30 发布日期:2025-08-08
  • 通讯作者: 沈勇,Email:shenyong84100@163.com

An analysis on the relationship between GLUT-1, CDK4 and clinical pathological characteristics and prognosis of patients with primary liver cancer

FENG Shi-chuan1, SHEN Yong2   

  1. 1. Department of General Practice,Hanzhong Central Hospital, Shaanxi 723000, China;
    2. Intervention and Vascular Surgery,Hanzhong Central Hospital, Shaanxi 723000, China
  • Received:2024-08-09 Online:2025-06-30 Published:2025-08-08
  • Contact: SHEN Yong,Email:shenyong84100@163.com

摘要: 目的 探讨葡萄糖转运蛋白1(GLUT-1)、细胞周期蛋白依赖激酶4(CDK4)与原发性肝癌患者临床病理特征和预后关系。方法 纳入 2018年12月至2021年6月汉中市中心医院收治的86例原发性肝癌患者,所有患者均接受手术治疗并进行病理学检查,随访时间为3年。比较癌组织、癌旁组织中GLUT-1、CDK4含量。分析原发性肝癌组织中GLUT-1、CDK4表达与临床病理特征以及患者预后的关系。绘制Kaplan-Meier生存曲线,对GLUT-1、CDK4与原发性肝癌患者预后关系进行评估。结果 患者癌组织中GLUT-1、CDK4表达阳性率分别为66.28%(57/86)、62.79%(54/86),均明显高于癌旁组织的22.09%(19/86)、18.60%(16/86)(P<0.05)。肝癌组织GLUT-1阳性表达患者3年累积生存率为42.11%(24/57) ,明显低于肝癌组织GLUT-1阴性表达患者的79.31%(23/29)(P<0.05);肝癌组织CDK4阳性表达患者3年累积生存率为46.30%(25/54) ,明显低于肝癌组织CDK4阴性表达患者的68.75% (22/32)(P<0.05)。血管侵犯及淋巴结转移为影响患者预后的独立危险因素。结论 GLUT-1、CDK4与原发性肝癌患者临床分期及分化程度密切相关,可作为评估患者病情进展及不良预后的重要指标。

关键词: 原发性肝癌, GLUT-1, CDK4, 病理特征, 预后

Abstract: Objective To explore the relationship between GLUT-1, CDK4 and the clinical pathological characteristics and prognosis of patients with primary liver cancer. Methods Eighty-six patients with primary liver cancer admitted from December 2019 to June 2021 were included as the study subjects. All patients underwent surgical treatment and pathological examination, with a follow-up period of 3 years. The levels of GLUT-1 and CDK4 in cancer tissues and adjacent tissues were detected and compared. According to the prognosis, the patients were divided into a good prognosis group and a poor prognosis group. The relationship between the expression of GLUT-1 and CDK4 in primary liver cancer tissues and clinical pathological characteristics, as well as patient prognosis were analyzed. The patients were grouped based on their clinical stage and differentiation degree, and compare the levels of GLUT-1 and CDK4 in the two groups of patients. Kaplan Meier survival curves were used to evaluate the relationship between GLUT-1, CDK4, and prognosis of patients with primary liver cancer. Results The positive rates of GLUT-1 and CDK4 expression in cancer tissues of patients were 66.28% and 62.79%, respectively, which were significantly higher than those in adjacent tissues (22.09% and 18.60%, respectively) (P<0.05); There were significant differences (P<0.05) in lymphatic vessel metastasis and vascular invasion among liver cancer patients with positive expression of GLUT-1 and CDK4; The three-year cumulative survival rate of patients with GLUT-1 positive expression in liver cancer tissue was 42.11% (24/57), which was significantly lower than that of 79.31% (23/28) patients with GLUT-1 positive expression in liver cancer tissue (P<0.05); The three-year cumulative survival rate of patients with CDK4 positive expression in liver cancer tissue was 46.30% (25/54), which was significantly lower than that of 68.75% (22/32) patients with GLUT-1 negative expression in liver cancer tissue (P<0.05); Vascular invasion, and lymph node metastasis are independent risk factors affecting patient prognosis. Conclusion GLUT-1 and CDK4 are closely related to the clinical stage and differentiation degree of primary liver cancer patients, and can be used as important indicators to evaluate the patients' progression and poor prognosis.

Key words: Primary liver cancer, GLUT-1, CDK4, Pathological features, prognosis